Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-097720 Size: 14 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-097716 Size: 8 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-097717 Size: 8 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-097718 Size: 8 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-097719 Size: 8 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-20-009653 Act: 34 Size: 8 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-20-009633 Act: 34 Size: 474 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-090332 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-090334 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-090283 Size: 4 KB 网页链接